• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

    6.640 +0.240 (+3.75%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Recursion Pharmaceuticals Inc Cl A

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Peering Into Recursion Pharmaceuticals's Recent Short Interest
    Via Benzinga
    10 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
    In an environment where the typical small biotech name is riskier than not, this one is curiously different. 
    Via The Motley Fool
    Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
    The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
    Via Benzinga
    Topics ETFs Stocks
    Exposures US Equities
    Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
    Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Is Recursion Pharmaceuticals Stock a Buy?
    It largely depends on your investing style. 
    Via The Motley Fool
    Looking Into Recursion Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
    Via Benzinga
    3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
    This company stands to benefit from a shifting pharmaceutical industry landscape. 
    Via The Motley Fool
    Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Prediction: These 2 Stocks Could Soar in 2025
    The key word here is "could." 
    Via The Motley Fool
    Cathie Wood Is Betting on This AI Stock: Is It a Buy?
    Wood has a stake in this stock, but it's hardly an "all-in" bet. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    How Is The Market Feeling About Recursion Pharmaceuticals?
    Via Benzinga
    Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
    This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
    The popular growth investor keeps adding to some of her favorite falling stocks. 
    Via The Motley Fool
    2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
    These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
    The Ark Invest portfolio is known for taking aggressive bets. 
    Via The Motley Fool
    AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    These AI-Related Stocks Were Down +10% Week Ending September 6
    AI-related tech stocks plummeted this week with the August ISM manufacturing index report that figures that came in below consensus expectations raising fears about the strength of the economy and that... 
    Via Talk Markets
    Topics Economy
    Exposures Economy Interest Rates
    Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
    The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
    Via Talk Markets
    Topics Economy
    Exposures Economy
    Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Nasdaq Dips Over 2%; US Construction Spending Falls In July
    Via Benzinga
    Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
    Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation... 
    Via Benzinga
    Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
    REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Is Recursion Pharmaceuticals a Warren Buffett Stock?
    Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. 
    Via The Motley Fool
    Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
    Via Talk Markets
    The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
    Merging with a former rival will bolster its capabilities. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.